Our current market cap is mostly based on the net
Post# of 30025
Posted On: 10/09/2014 2:03:33 PM
Our current market cap is mostly based on the net present value of the 2015 revenue Lympro is expected to bring in. A small amount of our market cap is based on MANF, since it is so pre-clinical. Getting IND orphans in January will help a little. But most of our increase in stock price between now and January will be due to increased confidence in Lympro's revenues.
Eltoprazine and Phenoguard have not influenced our stock price in the least, IMHO. When Elto starts it's trials in January, we'll get a small bump. But not until it successfully completes it's trial at the end of 2015 will we see a more significant bump. But by that time it will not be nearly as noticeable because Lympro will be driving up the pps very fast!
John's pet project is Phenoguard.
David Lowe's pet project is Eltoprazine.
I hope one day these pet projects will add value to AMBS, but I don't believe they'll ever make much of a difference compared to the difference LymPro and MANF will make.
I responded because you seemed to be taking a shot at me for my focus on LymPro and MANF and my lack of focus on the other two.
My comment on "spite" was referencing people like Solantey throwing up selling resistance on an obvious great day. If you disagree with that, that is fine, but I don't know why you would belittle me? I think my due diligence and contribution to this mb has been on par with yours.
Eltoprazine and Phenoguard have not influenced our stock price in the least, IMHO. When Elto starts it's trials in January, we'll get a small bump. But not until it successfully completes it's trial at the end of 2015 will we see a more significant bump. But by that time it will not be nearly as noticeable because Lympro will be driving up the pps very fast!
John's pet project is Phenoguard.
David Lowe's pet project is Eltoprazine.
I hope one day these pet projects will add value to AMBS, but I don't believe they'll ever make much of a difference compared to the difference LymPro and MANF will make.
I responded because you seemed to be taking a shot at me for my focus on LymPro and MANF and my lack of focus on the other two.
My comment on "spite" was referencing people like Solantey throwing up selling resistance on an obvious great day. If you disagree with that, that is fine, but I don't know why you would belittle me? I think my due diligence and contribution to this mb has been on par with yours.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼